Study Stopped
Test products expired.
Pre-meal Protein Drink Improve Glycemic Regulation
PMB/T2D
Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes
1 other identifier
interventional
35
1 country
1
Brief Summary
The purpose of this study is to investigate if a pre-meal drink containing proteins can positively influence glycaemic control in patients with type 2 diabetes mellitus. Comparison with a placebo is included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1 type-2-diabetes-mellitus
Started Jan 2014
Longer than P75 for phase_1 type-2-diabetes-mellitus
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 12, 2013
CompletedFirst Posted
Study publicly available on registry
November 19, 2013
CompletedStudy Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedMay 12, 2016
May 1, 2016
1.5 years
November 12, 2013
May 11, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
HbA1c
Glycated hemoglobin
16 weeks
Secondary Outcomes (1)
Postprandial glycemia
16 weeks
Other Outcomes (1)
Homeostasis model assessment of insulin resistance (HOMA-IR)
16 weeks
Study Arms (2)
Pre-meal protein drink
EXPERIMENTALA dose of 100 ml is taken just before breakfast, lunch and dinner.
Water drink
PLACEBO COMPARATORA dose of 100 ml is taken just before breakfast, lunch and dinner.
Interventions
Eligibility Criteria
You may qualify if:
- diagnosed type 2 diabetes mellitus according to WHO criteria (1999)
- age between 30-80 years
- non well controlled diabetes with HbA1c-levels above 62 mmol/mol
You may not qualify if:
- pregnant or risk of becoming pregnant
- severe disease
- psychological disease, dementia or mental disability that makes it impossible to retrieve informed consent of participation
- liver disease
- kidney malfunction (GFR \<60 or aspartate transaminase (ASAT)/alanine transaminase (ALT) two times higher than the normal interval
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lund Universitylead
- Landstinget i Kalmar Läncollaborator
Study Sites (1)
Lindsdals hälsocentral
Kalmar, 39365, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
November 12, 2013
First Posted
November 19, 2013
Study Start
January 1, 2014
Primary Completion
July 1, 2015
Study Completion
July 1, 2015
Last Updated
May 12, 2016
Record last verified: 2016-05